NCT03687515View on ClinicalTrials.gov

Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 3, 2016

Study Completion Date

November 30, 2017

Conditions

Chronic Rhinosinusitis With Polyposis

Interventions

DRUG

budesonide

1mg/2ml Pulmicort Respules BIS twice daily

DRUG

budesonide

nasal spray 256μg BID

DRUG

Prednisone

oral prednisone 24mg QD

All Listed Sponsors

lead

Beijing Tongren Hospital

OTHER

NCT03687515 - Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis. | Biotech Hunter | Biotech Hunter